Feasibility of Patient-Centered Home Care (PCHC) to Reduce Disparities in High-Risk Black Men (BM) With Prostate Cancer (CaP)

Mayo Clinic

Status

Enrolling

Conditions

Prostate Adenocarcinoma

Treatments

Other: Non-Interventional Study

Study type

Observational

Funder types

Other

Other U.S. Federal agency

Identifiers

NCT06470750

NCI-2024-04792 (Registry Identifier)

CaP PCHC (Other Identifier)

W81XWH2210969 (Other Grant/Funding Number)

W81XWH2210968 (Other Grant/Funding Number)

22-004375 (Other Identifier)

Details and patient eligibility

About

This study evaluates the possibility of patient-centered home care as a new model of cancer care to reduce disparities and improve health related quality of life and patient-reported outcomes in Black patients with prostate cancer.

Full description

PRIMARY OBJECTIVES:

I. To evaluate a highly innovative project evaluating the feasibility of patient-centered home care PCHC as a new model of cancer care to reduce disparities and improve health related QoL (HRQoL) and patient reported-outcomes (PROs) in Black patients with advanced prostate cancer (CaP). (Phase I) II. Establish patient-centeredness by exploring patients' choice relative to the place of CaP treatment for certain aspects of therapy as well as end-of-life care.

III. Establish the acceptance and impact of PCHC on PROs and HRQoL in BM with advanced CaP.

OUTLINE: This is an observational study. Participants are assigned to 1 of 2 groups.

GROUP 1: Participants take part in a focus group or complete questionnaires and may take part in an interview on study.

GROUP 2: Participants complete questionnaires throughout the study.

Enrollment

77 estimated patients

Sex

Male

Ages

18+ years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

GROUP 1 FOCUS GROUPS:
- Individuals identifying as Black and male who are familiar with the landscape of medical care and cancer
GROUP 1 SURVEYS:
- Are 18 years of age or older
- Have histologic evidence of prostate adenocarcinoma
- Are requiring, have required, or will require prostate cancer treatment
- Have an understanding of the protocol and its requirements
- Are willing to fill in a questionnaire and participate in a focused interview
- Are able and willing to sign an informed consent
GROUP 1 INTERVIEWS:
- Enrollment in the survey phase of the protocol
GROUP 2:
- Are 18 years of age or older
- Are Black men or other discounted patients (older adults, individuals residing in rural or remote areas, and those facing transportation challenges)
- Have histologic evidence of prostate adenocarcinoma
- Are requiring active standard hormone-based therapies (degarelix or leuprolide), antibone resorptive agents (zoledronic acid or denosumab), oral anticancer treatments (abiraterone or second-generation androgen receptor blockers) or intravenous chemotherapy (docetaxel)
- Are receiving part of supportive care/symptom management and/or anti-cancer therapy in the home as part of Cancer Care Beyond Walls (CCBW)
- Have an understanding of the protocol and its requirements
- Are able and willing to sign informed consent

Exclusion criteria

GROUP 1 FOCUS GROUPS:
- Individuals who do not identify as Black or male or who have had no extensive interaction with the healthcare system
GROUP 1 SURVEYS:
- Do not identify as Black men
- Have not been diagnosed with prostate cancer
GROUP 1 INTERVIEWS:
- Not enrolled in the survey phase of the protocol
GROUP 2:
- Do not identify as Black men or other discounted patients (older adults, individuals residing in rural or remote areas, and those facing transportation challenges)
- Have not been diagnosed with histologic evidence of prostate adenocarcinoma
- Are not requiring active standard anti-cancer therapy